<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of Fanconi anemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of Fanconi anemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of Fanconi anemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy S Olson, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter Newburger, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2459599684">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fanconi anemia (FA) is a rare inherited bone marrow failure syndrome (IBMFS) characterized by pancytopenia, predisposition to malignancy, and characteristic physical abnormalities/congenital malformations. FA is caused by pathogenic variants (ie, mutations) in one of numerous genes involved with deoxyribonucleic acid (DNA) repair. The diagnosis is usually made in childhood, but some individuals are not diagnosed until adulthood, due to variable disease manifestations and diagnostic delays.
        </p>
        <p>
         It is important to define FA as the cause of bone marrow failure. Individuals with FA require increased surveillance for organ dysfunction and cancers, reduced doses of chemotherapy and/or radiation must be used for treating cancers or prior to hematopoietic cell transplantation, and FA must be excluded in sibling donors for hematopoietic cell transplantation (HCT) to avoid transplantation with a graft from an undetected, asymptomatic sibling with FA.
        </p>
        <p>
         This topic discusses the clinical manifestations, diagnosis, and differential diagnosis of FA.
        </p>
        <p>
         Management and prognosis of FA are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/109777.html" rel="external">
          "Management and prognosis of Fanconi anemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">
          "Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4236793377">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         FA is an inherited disorder in which cells cannot properly repair DNA damage, which leads to genomic instability, disordered cell cycle regulation, and cell death.
        </p>
        <p>
         FA is caused by an inability to properly repair DNA interstrand crosslinks (ICLs), an especially deleterious type of DNA damage in which opposing strands of DNA are abnormally joined. Disordered repair of ICLs leads to genomic instability, aberrant cell cycle regulation, and cell death. DNA damage can occur during fetal development, which can cause congenital anomalies, and during childhood and adulthood, which is associated with bone marrow failure (BMF), organ damage, and cancer. (See
         <a class="local">
          'Genomic instability'
         </a>
         below and
         <a class="local">
          'Bone marrow failure'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H846978367">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         FA can be caused by pathogenic variants (ie, mutations) in numerous genes that encode proteins involved in DNA repair. (See
         <a class="local">
          'FA-associated genes'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2926523515">
         <span class="h3">
          Inheritance
         </span>
         <span class="headingEndMark">
          —
         </span>
         FA is caused by mutations in one of ≥22 different genes, which are described as
         <em>
          FANCA
         </em>
         to
         <em>
          FANCW
         </em>
         [
         <a href="#rid1">
          1-15
         </a>
         ]. Most cases of FA are inherited in an autosomal recessive pattern, but other patterns of inheritance are seen with certain FA-associated genes.
        </p>
        <p>
         The most commonly mutated genes are
         <em>
          FANCA
         </em>
         ,
         <em>
          FANCC
         </em>
         , and
         <em>
          FANCG
         </em>
         ; some FA-associated genes were previously recognized in other settings with different names (eg,
         <em>
          FANCS
         </em>
         was independently recognized as
         <em>
          BRCA1
         </em>
         ). Pathogenic variants of FA genes include point mutations, large deletions, and gene duplications [
         <a href="#rid16">
          16
         </a>
         ]. Genotype-phenotype correlations have been described for certain FA genes [
         <a href="#rid15">
          15,17,18
         </a>
         ].
        </p>
        <p>
         For most FA genes, inheritance follows an autosomal recessive pattern; thus, loss of normal function at both alleles is required to manifest disease, either with a homozygous pathogenic variant or compound heterozygous variants in an individual gene. Exceptions include
         <em>
          FANCR
         </em>
         , which
         <em>
         </em>
         is inherited with an autosomal dominant pattern and
         <em>
          FANCB
         </em>
         , which is X-linked recessive.
        </p>
        <p>
         Individuals who are heterozygous for variants in FA genes other th
         <em>
          an FANCB
         </em>
         and
         <em>
          FANCR
         </em>
         are considered unaffected carriers, although some of these individuals may have an increased susceptibility to cancer. (See
         <a class="local">
          'Findings in heterozygotes'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3397145044">
         <span class="h3">
          FA-associated genes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations of
         <em>
          FANCA
         </em>
         ,
         <em>
          FANCC
         </em>
         , and
         <em>
          FANCG
         </em>
         are the most common FA complementation groups  (
         <a class="graphic graphic_table graphicRef138971" href="/z/d/graphic/138971.html" rel="external">
          table 1
         </a>
         ); together, variants in these three genes account for 80 to 90 percent of cases of FA [
         <a href="#rid19">
          19,20
         </a>
         ]. Mutations of
         <em>
          FANCD1
         </em>
         are less common, but this complementation group has distinctive features, including earlier onset of malignancies.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           FANCA
          </em>
         </strong>
         – Mutations in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607139&amp;token=87jLzclRwWxNoI%2BQq5Gg77sEySNjig5uZzUJ8rmyVZKzQaTleJQKnUoTY2JdPEcM&amp;TOPIC_ID=109795" target="_blank">
          FANCA
         </a>
         are responsible for most cases of FA (approximately 60 to 65 percent) [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More than 200 distinct pathogenic alleles of
         <em>
          FANCA
         </em>
         have been identified; thus, in most cases,
         <em>
          FANCA
         </em>
         alleles are unique to individual pedigrees [
         <a href="#rid7">
          7
         </a>
         ]. Large intragenic deletions are common, though point mutations, smaller insertions/deletions, and splicing mutations are also frequent [
         <a href="#rid23">
          23
         </a>
         ]. Genotype-phenotype correlations within the
         <em>
          FANCA
         </em>
         group show that, compared with individuals who have at least one hypomorphic mutation, patients with two mutations leading to null alleles have earlier onset of hematologic abnormalities, higher risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and shorter survival after diagnosis [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           FANCC
          </em>
         </strong>
         – Mutations in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F613899&amp;token=87jLzclRwWxNoI%2BQq5Gg78s%2BE9nDBRiGWUCuABMZmnrtpuoVSsCDj6Vpbt9kGlCU&amp;TOPIC_ID=109795" target="_blank">
          FANCC
         </a>
         <em>
         </em>
         account for 10 to 15 percent of cases of FA [
         <a href="#rid1">
          1
         </a>
         ]. Compared with patients who have
         <em>
          FANCA
         </em>
         mutations, individuals with
         <em>
          FANCC
         </em>
         variants generally have a less severe hematologic course and lower incidences of congenital microcephaly and radial ray abnormalities [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most common mutations of
         <em>
          FANCC
         </em>
         are 322delG in exon 1 and IVS4+4A&gt;T in intron 4 [
         <a href="#rid7">
          7
         </a>
         ]. The IVS4+4A&gt;T variant is especially common in Ashkenazi Jews, and this variant along with Arg548Ter and Leu554Pro substitutions in exon 14 are associated with more congenital anomalies and earlier onset of hematologic abnormalities than the 322delG variant [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           FANCG
          </em>
         </strong>
         – Mutations in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F602956&amp;token=87jLzclRwWxNoI%2BQq5Gg79Wy8qcJ4xwlLSbdFNJi8664nGd5CZK71pPIDkkgdNmz&amp;TOPIC_ID=109795" target="_blank">
          FANCG
         </a>
         (also called
         <em>
          XRCC9
         </em>
         ) account for approximately 10 percent of cases of FA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Compared with mutations in
         <em>
          FANCA
         </em>
         or
         <em>
          FANCC,
         </em>
         mutations of
         <em>
          FANCG
         </em>
         are associated with similar frequencies of non-hematologic anomalies but more severe cytopenias and higher rates of hematologic malignancies [
         <a href="#rid1">
          1
         </a>
         ]. The 637-643delTACCGCC deletion in
         <em>
          FANCG
         </em>
         is thought to represent a founder mutation responsible for &gt;80 percent of FA cases in the Black South African population [
         <a href="#rid26">
          26
         </a>
         ]. The IVS3+1G&gt;C and 1066C&gt;T mutations in
         <em>
          FANCG
         </em>
         are common in Japanese and Korean populations, respectively [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           FANCD1
          </em>
         </strong>
         –
         <em>
          FAND1
         </em>
         is identical to the gene that was independently identified as
         <em>
          BRCA2
         </em>
         ; it
         <em>
         </em>
         accounts for approximately 3 percent of cases of FA [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Numerous mutations of
         <em>
          FANCD1
         </em>
         have been described. Patients have earlier onset of both AML and solid tumors and should undergo more aggressive screening protocols using magnetic resonance imaging (MRI) [
         <a href="#rid29">
          29-32
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Updated information on FA gene mutations is available from an FA mutation database:
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww2.rockefeller.edu%2Ffanconi%2F&amp;token=YnJoh4vhQs3hG%2B6v7Yp5HmJqbPIOQtkWoks4O8UhGp21OMjtyJ0hyrwijSLTRH5D&amp;TOPIC_ID=109795" target="_blank">
          www.rockefeller.edu/fanconi/
         </a>
        </p>
        <p class="headingAnchor" id="H4145134549">
         <span class="h2">
          Genomic instability
         </span>
         <span class="headingEndMark">
          —
         </span>
         FA proteins are needed to maintain genomic stability.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes and results of genomic instability
         </strong>
         – Loss of FA gene function causes aberrant repair of DNA ICLs, which interferes with normal DNA replication and transcription by preventing strand separation, stalling replication forks, and compromising DNA integrity [
         <a href="#rid33">
          33
         </a>
         ]. ICLs arise from endogenous aldehydes (eg, products of lipid peroxidation), exogenous aldehydes (eg, formed after alcohol consumption), and from exposure to radiation and DNA alkylating agents used as cancer chemotherapy. Aberrant repair of ICLs causes genomic instability, abnormal cell cycle regulation, and cell death. FA proteins also interact with other DNA damage response pathways and participate in stress response pathways (eg, oxidative stress).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FA core complex
         </strong>
         – The FA core complex is a multicomponent complex that forms at the site of a DNA ICL and contains eight of the known FA proteins: FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         FANCL is an E3 ubiquitin ligase that serves as the catalytic component of the core complex. It interacts with FANCT (UBE2T) to monoubiquitinate the ID complex (a heterodimer of FANCD2 and FANCI), which is incorporated into nuclear foci, where it recruits an endonuclease complex (FANCP and FANCQ), which unhooks the aberrant crosslink and creates a DNA double strand break (DSB). FANCD1 (identical to
         <em>
          BRCA2
         </em>
         , the breast cancer susceptibility gene),
         <em>
         </em>
         FANCN, FANCJ, and FANCO
         <em>
         </em>
         then work via the DSB DNA repair pathway to restore DNA integrity, using nucleotide excision repair and homologous recombination during the S or G2 phases of the cell cycle [
         <a href="#rid2">
          2,7,36-38
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         FA proteins also interact with other DNA damage response pathways, including proteins encoded by the ataxia-telangiectasia genes (
         <em>
          ATM
         </em>
         and
         <em>
          ATR
         </em>
         ) and the Nijmegen breakage syndrome (NBS) protein, nibrin (encoded by
         <em>
          NBN
         </em>
         ) [
         <a href="#rid2">
          2,39-43
         </a>
         ]. FA proteins also participate in oxidative stress response [
         <a href="#rid20">
          20,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3549934086">
         <span class="h2">
          Bone marrow failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         BMF in FA refers to a deficiency or impairment of hematopoietic stem cells (HSCs) that causes bone marrow hypoplasia leading to single or multiple cytopenias and eventual aplasia with pancytopenia.
        </p>
        <p>
         BMF is caused by premature, selective attrition of CD34+ HSCs, which can be observed prior to the onset of cytopenias. The precise mechanisms of stem cell loss are uncertain, but they include defective DNA repair leading to increased DNA damage and cell cycle arrest, increased levels of reactive oxygen species (ROS) and circulating inflammatory cytokines, and excessive damage from reactive aldehydes in the absence of intact FA repair pathways [
         <a href="#rid45">
          45-48
         </a>
         ]. Chronic stress-induced HSC activation caused by dysregulated oxidative stress and inflammatory cytokine exposure in the bone marrow microenvironment also contributes to BMF [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Endogenous aldehydes appear to affect HSCs during development [
         <a href="#rid49">
          49
         </a>
         ]. To illustrate the importance of endogenous aldehydes in this process, accelerated progression of BMF was reported in a series of 64 patients with FA who were deficient in acetaldehyde dehydrogenase 2 [
         <a href="#rid50">
          50
         </a>
         ]. Other mechanisms that have been implicated in HSC attrition include an increase in the level of inflammatory cytokines, DNA damage response (DDR)-induced NK cell activation, and abnormal telomere shortening [
         <a href="#rid51">
          51-53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3359991449">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         While rare, FA is the most common inherited bone marrow failure syndrome (IBMFS). The incidence has been estimated to be 1 in 300,000 live births and the prevalence of 1 to 9 per million, but the carrier frequency varies according to the population studied [
         <a href="#rid54">
          54
         </a>
         ]. FA has been described in nearly all races and ethnic groups.
        </p>
        <p>
         Most individuals are diagnosed with FA between six and nine years of age (concurrent with the onset of bone marrow failure), but recognition of the variable clinical manifestations and increased disease awareness are leading to earlier diagnoses [
         <a href="#rid55">
          55
         </a>
         ]. As many as 9 percent of individuals are diagnosed after age 16 years, typically, when they present with a malignancy [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
         Specific founder mutations account for a higher incidence of FA in certain populations. As examples, the
         <em>
          FANCA
         </em>
         c.295C&gt;T mutation is found in Spanish Romani populations, the
         <em>
          FANCC
         </em>
         IVS4 + 4A&gt;T mutation in Ashkenazi Jews, exon 15 deletions in patients of North African and Middle Eastern descent, a large intragenic deletion in the South African Afrikaner population, and others [
         <a href="#rid27">
          27,58-65
         </a>
         ]. The carrier frequency varies according to the populations studied. In the general population, the carrier frequency is 1 in ~190, but it is 1 in 100 in the Afrikaans population in South Africa, 1 in 100 in Ashkenazi Jews, and up to 1 in 64 in Spanish Romani populations [
         <a href="#rid58">
          58,59,63,64
         </a>
         ]. Founder mutations have also been identified in people from Tunisia, Japan, Korea, and Brazil [
         <a href="#rid27">
          27,60,65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3290687756">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         FA is typically associated with cytopenias, predisposition to malignancy, and congenital and developmental abnormalities. Some individuals have only modest or isolated cytopenias (eg, macrocytic anemia, thrombocytopenia) for years before they are recognized as having FA.
        </p>
        <p class="headingAnchor" id="H2260946219">
         <span class="h2">
          Congenital anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital malformations are the most common presenting features of FA  (
         <a class="graphic graphic_table graphicRef71159" href="/z/d/graphic/71159.html" rel="external">
          table 2
         </a>
         ), but an absence of such findings does not eliminate the possibility of FA.
        </p>
        <p>
         Malformations have been reported in 60 to 75 percent of individuals with FA, but this is likely an underestimate, as many patients do not manifest classical physical findings [
         <a href="#rid66">
          66
         </a>
         ]. The &lt;5 percent of cases that are diagnosed in the first year of life are usually due to recognition of classic congenital anomalies. Increasingly, gene sequencing panels identify individuals with non-classical or subtle findings.
        </p>
        <p>
         In a series of 419 patients in the International FA Registry, one-third lacked an obvious congenital abnormality, even though most had short stature, skin pigmentation abnormalities, or microphthalmia [
         <a href="#rid67">
          67
         </a>
         ]. In a series of 20 patients with FA who underwent brain magnetic resonance imaging (MRI), 90 percent had at least one abnormality, such as a small pituitary gland or an abnormality of the posterior fossa or corpus callosum [
         <a href="#rid68">
          68
         </a>
         ]. Ophthalmologic abnormalities such as microcornea, microphthalmia, and visual processing defects may also be underreported [
         <a href="#rid69">
          69,70
         </a>
         ]. In the US National Institutes of Health (NIH) experience, 75 percent of patients had hearing loss or structural ear abnormalities, while 90 percent had an ophthalmologic abnormality [
         <a href="#rid66">
          66
         </a>
         ]. Small series have also reported dental anomalies, conductive hearing loss, and skull base/posterior fossa abnormalities [
         <a href="#rid71">
          71-74
         </a>
         ].
        </p>
        <p>
         The most common developmental abnormalities in 370 patients enrolled in the International FA Registry and from a review of &gt;2000 patients reported in the literature (1927 to 2009) included [
         <a href="#rid66">
          66,75
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin
         </strong>
         (approximately 40 to 60 percent), including hyper- or hypopigmentation or café-au-lait spots
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Short stature
         </strong>
         (40 to 60 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thumb or other radial ray abnormalities
         </strong>
         (50 percent):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thumbs absent or hypoplastic, bifid/duplicated, rudimentary, triphalangeal (35 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Radii absent or hypoplastic (7 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other features, such as flat thenar eminence, clinodactyly, polydactyly, missing first metacarpal, dysplastic ulnae (6 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Axial skeleton
         </strong>
         (25 percent), especially microcephaly, triangular facies, short/webbed neck, vertebral anomalies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eyes
         </strong>
         (20 to 40 percent), including strabismus and hypo/hypertelorism
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney/urinary tract
         </strong>
         (approximately 20 to 30 percent), including horseshoe, ectopic, dysplastic, or absent kidney; hydronephrosis; hydroureter
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gonadal/genital
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In males, hypospadias, micropenis, undescended/absent testes, infertility (25 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In females, uterus malformation, small ovaries, hypogenitalia (&lt;5 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ear abnormalities
         </strong>
         (10 to 20 percent) with conductive hearing loss due to middle ear anomalies or atretic ear canal
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Congenital heart disease
         </strong>
         (approximately 5 percent), such as patent ductus arteriosus, ventricular septal defect, aortic coarctation, truncus arteriosus
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal
         </strong>
         (approximately 5 percent), such as tracheoesophageal fistula, esophageal atresia, intestinal atresia, imperforate anus
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central nervous system (CNS)
         </strong>
         (&lt;5 percent) involving the pituitary gland (eg, small, interrupted pituitary stalk syndrome), hydrocephalus, cerebellar hypoplasia, or absent corpus callosum
        </p>
        <p>
        </p>
        <p>
         FA is also associated with VACTERL-H, a syndrome in which individuals have ≥3 of the following: vertebral anomalies, anal atresia, congenital heart disease, tracheoesophageal fistula, esophageal atresia, renal anomalies, limb anomalies, and hydrocephalus. One-third of 54 patients with FA met criteria for VACTERL-H in an NIH study, although previous literature reviews had suggested only 5 percent had VACTERL-H [
         <a href="#rid76">
          76
         </a>
         ]. VACTERL-H is more common in patients with mutations of
         <em>
          FANCI
         </em>
         ,
         <em>
          FANCL
         </em>
         , and possibly
         <em>
          FANCB
         </em>
         , while it is less common in patients with
         <em>
          FANCD1
         </em>
         mutations [
         <a href="#rid29">
          29,77,78
         </a>
         ]. (See
         <a class="local">
          'VACTERL-H'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1306512416">
         <span class="h2">
          Cytopenias/bone marrow failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematologic manifestations of FA include thrombocytopenia, macrocytic anemia, or pancytopenia. Bone marrow failure (BMF) eventually occurs in most patients with FA, but the time to onset can be quite variable. Progression to pancytopenia can occur soon after initial cytopenias are noted, but it may take months or years to develop in other individuals; rarely, BMF does not develop at all.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytopenias
         </strong>
         – BMF is described as mild, moderate, or severe, according to the degree of cytopenias  (
         <a class="graphic graphic_table graphicRef57755" href="/z/d/graphic/57755.html" rel="external">
          table 3
         </a>
         ). Severe neutropenia and thrombocytopenia are especially problematic and can cause life-threatening infections and bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cytopenias may be mild initially or they may first present later in the disease course, especially if the diagnosis was made based on congenital anomalies. In some cases, only a single cell line (typically thrombocytopenia) will be involved, particularly early in life. Severe neutropenia (absolute neutrophil count [ANC] &lt;500/microL) and thrombocytopenia (platelet count &lt;30,000/microL) can cause infections and bleeding. Anemia is often the last severe cytopenia to develop; it is typically macrocytic, and some individuals have macrocytosis without anemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow failure
         </strong>
         – One study reported BMF in 80 percent of 754 patients at the time of enrollment in a FA registry; the cumulative incidence was 90 percent by age 40 years [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Specific genetic factors may protect certain patients from developing BMF. It arises less often in patients with biallelic
         <em>
          FANCD1/BRCA2
         </em>
         mutations, but this may reflect the high rate and early onset of malignancies, coupled with the short lifespan in this population. In addition, up to one-quarter of patients with FA may develop acquired somatic mosaicism through gene conversion events (in compound heterozygous patients), back mutation, or compensatory deletions/insertions, which lead to correction of the chromosomal breakage sensitivity phenotype [
         <a href="#rid79">
          79-82
         </a>
         ]. While many patients may have somatic mosaicism detectable only in lymphocytes, patients with mosaicism in hematopoietic stem/progenitor cell compartments have less BMF, although they remain at risk for hematologic malignancies and non-hematologic complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bone marrow findings with FA may be indistinguishable from those seen with other causes of BMF, such as aplastic anemia or myelodysplastic syndromes (MDS). For patients diagnosed in infancy due to congenital anomalies, screening bone marrow biopsies are often normocellular. However, by the onset of cytopenias, the marrow may reveal severe hypocellularity that is out of proportion to the degree of cytopenias. Bone marrow may reveal erythroid dysplasia (eg, hyperplastic erythroblast islands, megaloblastic features), but it should not be interpreted as MDS unless other features of MDS are also seen (eg, increased blasts or cytogenetic abnormalities). Conversely, dysplasia in the myeloid series, increased myeloblasts, or dysmegakaryopoiesis should be considered to be evidence for clonal abnormalities consistent with MDS [
         <a href="#rid20">
          20,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2526660423">
         <span class="h2">
          MDS/leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         MDS and leukemia are common with FA. In some cases, MDS or acute myeloid leukemia (AML) is the presenting finding. Lymphoid malignancies also occur, but they are much less common in most FA subtypes.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MDS/AML prevalence
         </strong>
         – Compared with the general population, the risk for MDS in patients with FA has been estimated to be increased 6000-fold, while the risk for AML was increased 700-fold; the lower prevalence of leukemia (3.1 percent) was presumably due to the early use of hematopoietic cell transplantation (HCT) in patients who developed MDS [
         <a href="#rid84">
          84
         </a>
         ]. A US National Cancer Institute (NCI) registry reported MDS in 16 percent of 163 patients after 15 year follow-up; the cumulative incidence of MDS was 80 percent by age 60 for patients who did not receive HCT [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Leukemia risk is especially high in patients with biallelic mutations in
         <em>
          FANCD1/BRCA2
         </em>
         ; these individuals have an 80 percent cumulative incidence of leukemia by age 10 [
         <a href="#rid29">
          29
         </a>
         ]. Most of these patients develop AML, although some may develop T cell acute lymphoblastic leukemia (ALL). Patients with
         <em>
          FANCD1/BRCA2
         </em>
         mutations involving the IVS7 site have particularly early risk of leukemia, with most developing AML by three years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Karyotypic abnormalities are common in patients with FA who develop MDS or AML, including translocations of chromosome 1p, monosomy 7, and gain of chromosome 3q [
         <a href="#rid20">
          20
         </a>
         ]. A literature review of 46 cases of AML in patients with FA found the most common cytogenetic abnormalities to be chromosomal gains of 1q, 3q, or 13q, along with loss of chromosome 7q [
         <a href="#rid86">
          86
         </a>
         ]. In contrast, cytogenetic lesions that are more common in de novo AML, including t(8;21), trisomy 8, and inv(16), were not seen in any of the patients with FA. In a study of 53 patients, 18 had 3q amplification, which was associated with shorter survival and increased risk for development of AML [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with FA who have any cytogenetic abnormality require close monitoring of the bone marrow and blood counts. Some cytogenetic abnormalities may remain stable or become undetectable over time, whereas loss of part or all of chromosome 7 is more likely to herald malignant progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of patients with FA and cytogenetic abnormalities is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/109777.html" rel="external">
          "Management and prognosis of Fanconi anemia", section on 'Hematologic neoplasms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphoid malignancies
         </strong>
         , including ALL and Burkitt lymphoma are also seen in patients with FA, but they are much less common than myeloid malignancies [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2548628516">
         <span class="h2">
          Solid tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Solid tumor types occur at increased frequency in individuals with FA and these tumors present at younger ages, compared with tumors in unaffected individuals. All patients with FA should undergo screening for cancers, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/109777.html" rel="external">
          "Management and prognosis of Fanconi anemia", section on 'Surveillance and prevention'
         </a>
         .)
        </p>
        <p>
         The most common tumors are squamous cell cancers (SCC) of skin and head/neck/tongue, skin basal cell carcinoma, and anogenital cancers. A malignancy is the presenting finding in many cases of FA that are not diagnosed until adulthood. Solid tumors are uncommon in children with FA (with the exception of patients with mutations of
         <em>
          FANCD1/BRCA2
         </em>
         ), but the annual risk increases with age, particularly in those &gt;30 years. Solid tumors are increasing as individuals with FA live longer, due in part, to more widespread use of HCT to cure BMF and increased long-term malignancy risk associated with HCT.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence of solid tumors
         </strong>
         – Solid tumors were seen in 20 percent of individuals with FA by age 60 in the US NCI registry; the most common tumors were SCC of skin and head/neck/tongue, skin basal cell carcinoma, and anogenital cancers [
         <a href="#rid85">
          85
         </a>
         ]. In a study that followed 754 patients for &gt;20 years, 28 percent developed a solid tumor by age 40 [
         <a href="#rid17">
          17
         </a>
         ]. SCC of the head, neck, esophagus, anus, and urogenital region were the most common solid tumors (49 percent); others included liver tumors (23 percent), kidney (8 percent), brain tumors (6 percent), breast (4 percent), and others (eg, germ cell tumors, sarcomas). Similar findings have been reported in other cohorts [
         <a href="#rid55">
          55,88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Association with age and HCT
         </strong>
         – The risk for developing a solid tumor increases in association with age in individuals with FA; this pattern differs from that with AML, for which the risk plateaus between age 30 to 40 [
         <a href="#rid17">
          17,55,84,88,89
         </a>
         ]. A study of 1300 individuals with FA estimated the median age of cancer development to be 16 years, compared with 68 years in the general population [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients who undergo HCT, exposure to DNA-damaging agents or radiation in the conditioning regimen and development of graft-versus-host disease (GVHD) further increase the risk of solid tumors. A study reported that, compared 145 patients with FA who did not undergo HCT, 117 individuals with FA who underwent HCT had a 4.4-fold higher age-specific hazard of SCC and the tumors occurred at a younger age (median age, 18 versus 33 years) [
         <a href="#rid91">
          91
         </a>
         ]. In another series of 37 individuals with FA who underwent HCT, the 15-year incidence of head and neck cancers was 53 percent [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patients with biallelic
         <em>
          FANCD1/BRCA2
         </em>
         mutations have especially high rates of cancer development. In one report, there was &gt;97 percent likelihood of developing a malignancy by age seven [
         <a href="#rid93">
          93
         </a>
         ]. By age five, brain tumors developed in more than one-half of patients with
         <em>
          FANCD1
         </em>
         , but new onset brain tumors were rare beyond this age [
         <a href="#rid84">
          84
         </a>
         ]. Wilms tumor is also common in patients with biallelic
         <em>
          FANCD1
         </em>
         mutations; other solid tumors of childhood are seen less often, including rhabdomyosarcoma and neuroblastoma [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
         The role of human papilloma virus (HPV) infection in patients with FA who develop SCC is unclear. A 2003 report from a United States cohort suggested that the high incidence of SCC of the head/neck and anal/urogenital regions in patients with FA was due to genomic instability produced by HPV, as &gt;80 percent of these tumors were HPV-positive [
         <a href="#rid94">
          94
         </a>
         ]. However, two subsequent reports contradicted these findings, demonstrating HPV DNA in only 2 of 21 and 1 of 9 patients (many of these tumors had mutated
         <em>
          TP53
         </em>
         ) [
         <a href="#rid95">
          95,96
         </a>
         ].
        </p>
        <p>
         The role of HPV vaccination in patients with FA is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/109777.html" rel="external">
          "Management and prognosis of Fanconi anemia", section on 'Solid tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H377291440">
         <span class="h2">
          Endocrine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with FA have a range of endocrine disorders, including thyroid, adrenal, and gonadal dysfunction; diabetes; and dyslipidemias.
        </p>
        <p>
         In many cases, endocrine abnormalities are caused by anatomical disruption of the hypothalamic-pituitary axis during development (eg, pituitary stalk interruption syndrome, septo-optic dysplasia) [
         <a href="#rid97">
          97
         </a>
         ]. In other cases, endocrine abnormalities may be intrinsic to FA or develop in association with the HCT conditioning regimen or treatment of GVHD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Short stature
         </strong>
         is seen in most individuals with FA, but some patients have normal or even above-average height regardless of genotype [
         <a href="#rid98">
          98
         </a>
         ]. Short stature may be intrinsic to FA, but in many cases, short stature is driven by growth hormone deficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary hypothyroidism
         </strong>
         is seen in over 60 percent of patients with FA, usually due to central hypothalamic or intrinsic thyroid dysfunction rather than autoimmunity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adrenal dysfunction
         </strong>
         occurs in a subset of patients due to low ACTH secretion, although these patients will generally have a normal response to exogenous ACTH stimulation [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes
         </strong>
         – Altered glucose metabolism, including diabetes mellitus and impaired glucose tolerance, occurs in nearly 50 percent of patients with FA due to dysfunction of pancreatic islet cells [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyslipidemia/metabolic syndrome
         </strong>
         – Patients with FA are also at increased risk for dyslipidemia and other aspects of metabolic syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gonadal
         </strong>
         – Infertility and delayed or abnormal progression of puberty are also very frequent in FA. In males, infertility may result from gonadal dysfunction and/or developmental defects in genital tract formation. In females, fertility is possible; however, premature ovarian failure occurs in over 75 percent of patients [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patients with these abnormalities require evaluation by an endocrinologist with expertise in FA. (See
         <a class="medical medical_review" href="/z/d/html/109777.html" rel="external">
          "Management and prognosis of Fanconi anemia", section on 'Identification and management of organ dysfunction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2887898203">
         <span class="h2">
          Findings in heterozygotes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals who are heterozygous for FA mutations do not develop BMF and are considered asymptomatic carriers, with the following exceptions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          FANCB
         </em>
         (X-linked recessive) and
         <em>
          FANCR
         </em>
         (autosomal dominant) are phenotypically manifest with mutations in a single allele.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoallelic
         <em>
          FANCS
         </em>
         and
         <em>
          FANCD1
         </em>
         mutations (also known as
         <em>
          BRCA1
         </em>
         and
         <em>
          BRCA2
         </em>
         , respectively) predispose to breast, ovarian, and other cancers; heterozygous mutations in
         <em>
          FANCN (PALB2)
         </em>
         and
         <em>
          FANCJ (BRIP1)
         </em>
         have also been identified as low to moderate penetrance breast and/or ovarian cancer susceptibility genes [
         <a href="#rid101">
          101-103
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The association between FA carrier status and increased cancer risk is less certain for other FA subtypes, but congenital anomalies are seen occasionally. Individuals who are heterozygous for mutations in ≥2 distinct FA genes do not develop classic FA features. However, a family with familial childhood ALL was found to have potentially pathogenic germline variants in both
         <em>
          FANCP
         </em>
         and
         <em>
          FANCA
         </em>
         [
         <a href="#rid104">
          104
         </a>
         ]. Large scale genomic studies are needed to determine if co-inheritance of ≥2 deleterious germline heterozygous mutations in distinct FA genes increases cancer susceptibility.
        </p>
        <p>
         The International FA Registry compared a cohort of 404 FA carriers with 329 non-carriers (relatives of individuals in the registry) and with the Surveillance, Epidemiology, and End Results (SEER) and Connecticut tumor registries [
         <a href="#rid105">
          105
         </a>
         ]. There was no increase of overall cancer incidence (standardized incidence ratio [SIR] relative to the United States population, 1 [95% CI 0.8-1.3]); however, there was a slightly higher risk of breast cancer in carrier grandmothers of individuals with FA (SIR 1.7 [95% CI 1.1-2.7]).
        </p>
        <p class="headingAnchor" id="H136536741">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation includes a history and physical examination, screening tests for defective DNA repair, and genetic testing to identify the specific genetic disorder. Clinical features associated with FA are described above. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
         Diagnostic delays are common, especially in individuals who do not develop bone marrow failure (BMF) early in their course. Early diagnosis is important because FA is associated with cancer predisposition and sometimes subtle congenital anomalies. Diagnosis is also important so that siblings can be tested to avoid hematopoietic cell transplantation (HCT) using a stem cell donor with the same genetic abnormality. Family planning with conception and preimplantation genetic testing of additional children can also be performed [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3651922990">
         <span class="h2">
          Indications for screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Screening for FA with chromosome breakage testing is needed urgently in any child or young adult with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Persistent moderate to severe cytopenias
         </strong>
         – Individuals with &gt;2 weeks of moderate or severe cytopenias in ≥2 lineages in the context of severely hypocellular bone marrow (&lt;25 percent of normal cellularity), in the absence of malignancy, cytotoxic therapy, active severe infection, or other known cause. (See
         <a class="local">
          'Cytopenias/bone marrow failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Characteristic physical findings
         </strong>
         – Findings that satisfy criteria for VACTERL-H (ie, ≥3 of the following: vertebral anomalies, anal atresia, congenital heart disease, tracheoesophageal fistula, esophageal atresia, renal anomalies, limb anomalies, and hydrocephalus) or multiple malformations, such as short stature, café-au-lait spots, thumb/radial ray abnormalities, or hypospadias that are strongly associated with FA. (See
         <a class="local">
          'Congenital anomalies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relative with FA diagnosis
         </strong>
         – Close relatives of a patient known to have FA; this is particularly important for relatives who are being evaluated as potential donors for HCT. (See
         <a class="medical medical_review" href="/z/d/html/109777.html" rel="external">
          "Management and prognosis of Fanconi anemia", section on 'Testing of siblings and management of heterozygotes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – Screening should also be considered in a child or adult with unexplained cytopenias (which may be mild, single lineage, or macrocytic) associated with characteristic congenital abnormalities; individuals ≤40 years with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or certain cytogenetic abnormalities (eg, partial or complete loss of chromosome 7; gain of 1q, 3q, or 13q); development of squamous cell cancer (SCC) of the head, neck, or anorectal region with no known attributable exposure; and patients who had severe toxicity with chemotherapy or radiation therapy [
         <a href="#rid20">
          20,107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1375668827">
         <span class="h2">
          Chromosome breakage testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hallmark of FA is defective DNA repair that causes extreme sensitivity to DNA interstrand crosslinking agents. Screening for FA involves exposure of cells to diepoxybutane (DEB) or
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         C (MMC) followed by assessment for chromosomal breakage [
         <a href="#rid56">
          56,108
         </a>
         ]. This screening should be performed with peripheral blood rather than bone marrow; in some cases (described below), chromosome breakage testing should use skin fibroblasts.
        </p>
        <p>
         Clinical and laboratory findings that suggest FA are described above. (See
         <a class="local">
          'Indications for screening'
         </a>
         above.)
        </p>
        <p>
         Screening tests are quite sensitive for FA, but not entirely specific, as a positive test can also be seen with other inherited disorders associated with chromosomal instability [
         <a href="#rid109">
          109
         </a>
         ]. Qualitative assessments of the patterns of abnormal breakage can help distinguish FA from other chromosome instability syndromes. With FA, there are increased rates of spontaneous breakage and increased breakage in response to both DEB and MMC; by contrast, increased breakage to MMC alone is more common in other chromosomal breakage syndromes and atypical features (eg, railroad figures, premature centromere separation) are seen exclusively in cohesinopathies [
         <a href="#rid110">
          110
         </a>
         ]. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Screening of peripheral blood is preferred to screening of bone marrow because testing is performed on T lymphocytes. In vitro expansion of cultured cells enables testing even in patients with severe leukopenia. For individuals with a high pre-test probability of FA and negative screening for chromosomal breakage with lymphocytes, we repeat the testing on skin fibroblasts, as T cells may show normal DNA repair due to somatic mosaicism or revertant mutations. Skin fibroblast testing is also needed for patients who have already undergone HCT [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Some experts proceed directly to genetic diagnosis without first performing screening tests. (See
         <a class="local">
          'Genetic testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H494308733">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Next-generation sequencing (NGS) is required to confirm the diagnosis of FA and to identify the specific molecular defect. NGS testing should be performed for all individuals with a positive chromosomal breakage test. (See
         <a class="local">
          'Chromosome breakage testing'
         </a>
         above.)
        </p>
        <p>
         NGS testing is essential for:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identifying the particular genetic abnormality, personalizing care according to genotype/phenotype correlations (eg, cancer screening in heterozygotes for mutations with increased risk of solid tumors), and excluding other chromosomal breakage disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapidly evaluating family members as potential transplant donors and to provide proper management for affected relatives.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prenatal testing and genetic counseling, given that heterozygous carriers will not have abnormal chromosomal breakage testing [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         NGS or whole-exome sequencing testing is now available to evaluate all genes associated with FA and can be performed through a number of laboratories, such as those listed on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=109795" target="_blank">
          Genetic Testing Registry website
         </a>
         .
        </p>
        <p>
         Testing for mutations in individual genes can be performed instead of NGS testing for family members of an individual with a known FA mutation.
        </p>
        <p>
         For most patients, DNA sequencing has replaced complementation group testing, which involves somatic cell fusions of patient cells with index cells for specific complementation groups. Complementation testing can also involve gene transfer of complementary DNA (cDNA) for known FA genes into patient cells and assessment for correction of an FA cellular phenotype. Although it is no longer performed routinely, it can be useful to define the functional subtype (ie, complementation group) of FA in situations where either no variants in FA genes are identified by NGS, if a variant of uncertain significance is detected in an FA gene, or if variants are seen in several distinct FA genes; in such cases, complementation analysis can be useful for attributing causality to a specific gene variant.
        </p>
        <p class="headingAnchor" id="H1060905424">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of FA includes other acquired and inherited causes of bone marrow failure (BMF)  (
         <a class="graphic graphic_table graphicRef52354" href="/z/d/graphic/52354.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3440929029">
         <span class="h2">
          Drug- or infection-associated cytopenias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medications, chemicals, certain viral infections, sepsis, or other severe bacterial infections can cause transient pancytopenia and bone marrow hypoplasia. These conditions are generally associated with transient and reversible cytopenias, patients lack congenital anomalies, and they can be conclusively distinguished from FA with a negative chromosomal breakage test.
        </p>
        <p class="headingAnchor" id="H690891488">
         <span class="h2">
          Immune cytopenias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Isolated cytopenias (eg, thrombocytopenia, anemia) caused by FA may be erroneously assumed to be caused by an immune mechanism. As an example, FA-associated thrombocytopenia is often initially considered to be due to immune thrombocytopenia (ITP). The presence of characteristic physical findings and the lack of response to immune-modulating therapies can help to distinguish immune cytopenias from FA.
        </p>
        <p class="headingAnchor" id="H2867862936">
         <span class="h2">
          Acquired aplastic anemia (AA)
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA is an acquired BMF syndrome caused by autoreactive T cell destruction of bone marrow stem and progenitor cells [
         <a href="#rid111">
          111
         </a>
         ]. AA often arises after exposure to environmental triggers in susceptible individuals, such as individuals with autoimmune thyroid disease or other autoimmune manifestations. Like FA, patients with AA often present between 5 to 15 years of age with multilineage cytopenias and bone marrow aplasia, but individuals with AA typically have a more rapid onset and progression of cytopenias, normal chromosomal breakage screening/DNA sequencing, lack characteristic FA-associated congenital anomalies and endocrine features, and respond to immunosuppressive therapy. (See
         <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">
          "Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5923.html" rel="external">
          "Treatment of acquired aplastic anemia in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3012580">
         <span class="h2">
          Paroxysmal nocturnal hemoglobinuria (PNH)
         </span>
         <span class="headingEndMark">
          —
         </span>
         PNH
         <strong>
         </strong>
         typically develops concurrent with or after the onset of immune-mediated AA and is associated with chronic hemolytic anemia and a high risk of thrombosis. In PNH, acquired mutations in the
         <em>
          PIGA
         </em>
         gene cause dominance of hematopoiesis by a clone of cells that lack glycosylphosphatidylinositol (GPI) anchors. PNH clones are never seen in patients with FA and detection of a CD55-negative or CD59-negative clone of cells is 100 percent specific for acquired BMF [
         <a href="#rid112">
          112
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">
          "Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">
          "Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1791860934">
         <span class="h2">
          Other IBMFS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other inherited bone marrow failure syndromes (IBMFS) can be associated with BMF. Some of these conditions may be suspected based on characteristic findings with chromosome breakage testing, as described above. (See
         <a class="local">
          'Chromosome breakage testing'
         </a>
         above.)
        </p>
        <p>
         Other IBMFS that should be distinguished from FA include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyskeratosis congenita (DC)
         </strong>
         – DC is an IBMFS associated with a characteristic triad of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia; predisposition to cancers, certain congenital anomalies, and liver or lung fibrosis. Individuals with DC have abnormal screening for chromosome breakage, but unlike FA, they have very short telomeres on telomere length analysis of peripheral blood lymphocytes. (See
         <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">
          "Dyskeratosis congenita and other telomere biology disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reticular dysgenesis (RD)
         </strong>
         – RD is a severe combined immunodeficiency caused by mutations in the
         <em>
          AK2
         </em>
         gene in which bone marrow aplasia develops in infancy in association with sensorineural hearing loss and severe adaptive immune dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">
          "Severe combined immunodeficiency (SCID): Specific defects", section on 'Reticular dysgenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other IBMFS
         </strong>
         – Shwachman-Diamond syndrome (SDS), congenital amegakaryocytic thrombocytopenia (CAMT), and Diamond-Blackfan anemia (DBA) can also be associated with multilineage cytopenias and bone marrow hypoplasia. As with FA, DBA can overlap with VACTERL-H, but pancytopenia in these IBMFS typically develops after an extended period of isolated neutropenia (SDS), thrombocytopenia (CAMT), or anemia (DBA). Individuals with these conditions have a negative chromosomal breakage test and, instead, have other mutations in specific genes. (See
         <a class="medical medical_review" href="/z/d/html/5914.html" rel="external">
          "Shwachman-Diamond syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/131283.html" rel="external">
          "Diamond-Blackfan anemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5921.html" rel="external">
          "Causes of thrombocytopenia in children", section on 'Inherited platelet disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H65382863">
         <span class="h2">
          VACTERL-H
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some cases of FA overlap with VACTERL-H (vertebral anomalies, anal atresia, congenital heart disease, tracheo-esophageal fistula, esophageal atresia, renal, limb anomalies, hydrocephalus) or PHENOS (pigmentation, small head, small eyes, central nervous system abnormalities other than hydrocephalus, otology, and short stature) syndromes [
         <a href="#rid76">
          76,85
         </a>
         ]. VACTERL-H can be seen in association with FA or other conditions (eg, DBA).
        </p>
        <p class="headingAnchor" id="H64384169">
         <span class="h2">
          Myelodysplastic syndromes (MDS)
         </span>
         <span class="headingEndMark">
          —
         </span>
         These clonal bone marrow neoplasms are characterized by cytopenias, morphologic dysplasia, and ineffective hematopoiesis [
         <a href="#rid113">
          113
         </a>
         ]. MDS can cause BMF with variable levels of cytopenias, multilineage dysplasia, cytogenetic abnormalities, and increased blasts. While MDS can develop in patients with FA, it can also arise from age-related clonal hematopoiesis or from other acquired/inherited BMF syndromes.
        </p>
        <p>
         Importantly, individuals with MDS in whom FA is being considered should have chromosomal breakage tests performed on skin fibroblasts rather than hematopoietic cells, because bone marrow cytogenetic abnormalities associated with MDS clones may skew chromosomal breakage results performed on lymphocytes. (See
         <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">
          "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3322450487">
         <span class="h2">
          Chromosome breakage syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain chromosomal instability syndromes are associated with sensitivity to ionizing radiation and variable sensitivity to DNA crosslinking agents used in chromosomal breakage testing. These rare disorders are associated with multiple congenital anomalies (eg, microcephaly, short stature) and predisposition to cancers, but they typically do not exhibit BMF (except in the setting of evolving malignancy). They can be distinguished from FA by DNA sequence analysis. These conditions (and the associated genes) include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nijmegen breakage syndrome (
         </strong>
         <strong>
          <em>
           NBS
          </em>
         </strong>
         <strong>
          )
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/3957.html" rel="external">
          "Nijmegen breakage syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bloom syndrome (
         </strong>
         <strong>
          <em>
           BLM
          </em>
         </strong>
         <strong>
          )
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">
          "Bloom syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ataxia telangiectasia (
         </strong>
         <strong>
          <em>
           ATM
          </em>
         </strong>
         <strong>
          )
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">
          "Ataxia-telangiectasia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LIG4 syndrome (
         </strong>
         <strong>
          <em>
           LIG4
          </em>
         </strong>
         <strong>
          )
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">
          "T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'XRCC4 and DNA ligase IV'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NHEJ1 deficiency (
         </strong>
         <strong>
          <em>
           NHEJ1
          </em>
         </strong>
         <strong>
          )
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">
          "T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'Nonhomologous DNA end joining (recombination and DNA repair)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seckel syndrome (
         </strong>
         <strong>
          <em>
           ATR
          </em>
         </strong>
         <strong>
          )
         </strong>
         <strong>
          <em>
          </em>
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cohesinopathies
         </strong>
         (eg, Roberts syndrome [
         <em>
          ESCO2
         </em>
         ], Cornelia de Lange syndrome [
         <em>
          NIPBL,
         </em>
         <em>
          SMC1
         </em>
         , or
         <em>
          SMC3
         </em>
         ], Warsaw breakage syndrome [
         <em>
          DDX11
         </em>
         ])
        </p>
        <p>
        </p>
        <p>
         Unlike FA, patients with NBS do not typically exhibit BMF, except in the setting of evolving malignancy. Also compared with FA, these conditions show subtle differences in the associated congenital anomalies, the spectrum of associated malignancies, and the specific abnormalities seen with chromosomal breakage testing (eg, increased chromosome 7 and 14 abnormalities in NBS, railroading figures in cohesinopathies). Nevertheless, gene sequencing distinguishes FA from NBS and other rare chromosomal breakage syndromes.
        </p>
        <p class="headingAnchor" id="H3595874157">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120173.html" rel="external">
          "Society guideline links: Bone marrow failure syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H341673553">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fanconi anemia (FA)
         </strong>
         – FA is an inherited bone marrow failure syndrome (IBMFS) in which cells cannot properly repair interstrand crosslinks (ICLs) in DNA. This results in increased sensitivity to cytotoxic therapies, predisposition to malignancies, characteristic congenital abnormalities, and bone marrow failure (BMF).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – FA can be caused by pathogenic variants (ie, mutations) in at least 22 distinct genes that are involved with DNA repair  (
         <a class="graphic graphic_table graphicRef138971" href="/z/d/graphic/138971.html" rel="external">
          table 1
         </a>
         ).
         <em>
          FANCA
         </em>
         ,
         <em>
          FANCC
         </em>
         , and
         <em>
          FANCG
         </em>
         are the most common categories (complementation groups). Most cases of FA exhibit autosomal recessive inheritance, but some FA-associated genes are inherited with other patterns; with few exceptions, individuals who are heterozygous for an FA mutation are considered asymptomatic carriers. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – FA is rare, but it is the most common IBMFS. Certain populations have a higher prevalence (eg, Spanish Romani populations, Ashkenazi Jews). (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – FA can present with characteristic congenital malformations  (
         <a class="graphic graphic_table graphicRef71159" href="/z/d/graphic/71159.html" rel="external">
          table 2
         </a>
         ) and/or findings associated with cytopenias/BMF; myelodysplastic syndromes (MDS), leukemia, or solid tumors (especially squamous cell cancers) may also be found. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for FA
         </strong>
         – The hallmark of FA is defective DNA repair that results in extreme sensitivity to DNA ICL agents (eg, diepoxybutane or
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         C). Chromosome breakage testing is indicated for a child or young adult with persistent cytopenias (eg, ≥2 weeks), characteristic physical abnormalities (eg, short stature, microcephaly, developmental delay, café-au-lait skin lesions), and other clinical findings. (See
         <a class="local">
          'Indications for screening'
         </a>
         above and
         <a class="local">
          'Chromosome breakage testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of FA requires DNA sequencing to identify a pathogenic variant in an FA-associated gene. (See
         <a class="local">
          'Genetic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         First-degree relatives of identified patients should be tested for proper management and to avoid affected individuals as potential transplant donors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Other conditions that should be distinguished from FA include other causes of pancytopenia (eg, infections, medications), immune cytopenias, acquired aplastic anemia, paroxysmal nocturnal hemoglobinuria, MDS, and rare IBMFS or chromosomal breakage syndromes  (
         <a class="graphic graphic_table graphicRef52354" href="/z/d/graphic/52354.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H360477001">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate acknowledges Akiko Shimamura, MD, PhD; and Alison Bertuch, MD, PhD, who contributed to earlier versions of this topic review.
        </p>
        <p>
         The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Faivre L, Guardiola P, Lewis C, et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. Blood 2000; 96:4064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003; 3:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005; 8:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007; 39:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Rocco D, Bottega R, Cappelli E, et al. Molecular analysis of Fanconi anemia: the experience of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Onco-Hematology. Haematologica 2014; 99:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hira A, Yoshida K, Sato K, et al. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia. Am J Hum Genet 2015; 96:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong H, Nebert DW, Bruford EA, et al. Update of the human and mouse Fanconi anemia genes. Hum Genomics 2015; 9:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rickman KA, Lach FP, Abhyankar A, et al. Deficiency of UBE2T, the E2 Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T Subtype of Fanconi Anemia. Cell Rep 2015; 12:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Virts EL, Jankowska A, Mackay C, et al. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia. Hum Mol Genet 2015; 24:5093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawyer SL, Tian L, Kähkönen M, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov 2015; 5:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang AT, Kim T, Wagner JE, et al. A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination. Mol Cell 2015; 59:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ameziane N, May P, Haitjema A, et al. A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51. Nat Commun 2015; 6:8829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JY, Virts EL, Jankowska A, et al. Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene. J Med Genet 2016; 53:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knies K, Inano S, Ramírez MJ, et al. Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia. J Clin Invest 2017; 127:3013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demuth I, Wlodarski M, Tipping AJ, et al. Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9. Eur J Hum Genet 2000; 8:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chandrasekharappa SC, Lach FP, Kimble DC, et al. Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia. Blood 2013; 121:e138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101:1249.
          </a>
         </li>
         <li class="breakAll">
          Fanconi Anemia Clinical Care Guidelines, Fifth Edition 2020. Fanconi Anemia Research Fund. https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf (Accessed on June 16, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peffault de Latour R, Soulier J. How I treat MDS and AML in Fanconi anemia. Blood 2016; 127:2971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soulier J. Fanconi anemia. Hematology Am Soc Hematol Educ Program 2011; 2011:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fanconi anaemia/Breast cancer consortium. Positional cloning of the Fanconi anaemia group A gene. Nat Genet 1996; 14:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996; 14:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castella M, Pujol R, Callén E, et al. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood 2011; 117:3759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verlander PC, Kaporis A, Liu Q, et al. Carrier frequency of the IVS4 + 4 A--&gt;T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. Blood 1995; 86:4034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillio AP, Verlander PC, Batish SD, et al. Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. Blood 1997; 90:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan NV, Essop F, Demuth I, et al. A common Fanconi anemia mutation in black populations of sub-Saharan Africa. Blood 2005; 105:3542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yagasaki H, Oda T, Adachi D, et al. Two common founder mutations of the fanconi anemia group G gene FANCG/XRCC9 in the Japanese population. Hum Mutat 2003; 21:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park J, Kim M, Jang W, et al. Founder haplotype analysis of Fanconi anemia in the Korean population finds common ancestral haplotypes for a FANCG variant. Ann Hum Genet 2015; 79:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 2007; 44:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Offit K. BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 2006; 98:1675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner JE, Tolar J, Levran O, et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 2004; 103:3226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers K, Davies SM, Harris RE, et al. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations. Pediatr Blood Cancer 2012; 58:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duxin JP, Walter JC. What is the DNA repair defect underlying Fanconi anemia? Curr Opin Cell Biol 2015; 37:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagby G. Recent advances in understanding hematopoiesis in Fanconi Anemia. F1000Res 2018; 7:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno OM, Paredes AC, Suarez-Obando F, Rojas A. An update on Fanconi anemia: Clinical, cytogenetic and molecular approaches (Review). Biomed Rep 2021; 15:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev 2010; 24:1680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Andrea AD. The Fanconi road to cancer. Genes Dev 2003; 17:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider M, Chandler K, Tischkowitz M, Meyer S. Fanconi anaemia: genetics, molecular biology, and cancer – implications for clinical management in children and adults. Clin Genet 2015; 88:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007; 8:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006; 107:4223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson LH. Unraveling the Fanconi anemia-DNA repair connection. Nat Genet 2005; 37:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006; 24:3799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy RD, Chen CC, Stuckert P, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007; 117:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longerich S, Li J, Xiong Y, et al. Stress and DNA repair biology of the Fanconi anemia pathway. Blood 2014; 124:2812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brosh RM Jr, Bellani M, Liu Y, Seidman MM. Fanconi Anemia: A DNA repair disorder characterized by accelerated decline of the hematopoietic stem cell compartment and other features of aging. Ageing Res Rev 2017; 33:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garaycoechea JI, Patel KJ. Why does the bone marrow fail in Fanconi anemia? Blood 2014; 123:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Li J, Sejas DP, Pang Q. Hypoxia-reoxygenation induces premature senescence in FA bone marrow hematopoietic cells. Blood 2005; 106:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadatzadeh MR, Bijangi-Vishehsaraei K, Hong P, et al. Oxidant hypersensitivity of Fanconi anemia type C-deficient cells is dependent on a redox-regulated apoptotic pathway. J Biol Chem 2004; 279:16805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridpath JR, Nakamura A, Tano K, et al. Cells deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of formaldehyde. Cancer Res 2007; 67:11117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hira A, Yabe H, Yoshida K, et al. Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood 2013; 122:3206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uziel O, Reshef H, Ravid A, et al. Oxidative stress causes telomere damage in Fanconi anaemia cells - a possible predisposition for malignant transformation. Br J Haematol 2008; 142:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briot D, Macé-Aimé G, Subra F, Rosselli F. Aberrant activation of stress-response pathways leads to TNF-alpha oversecretion in Fanconi anemia. Blood 2008; 111:1913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casado JA, Valeri A, Sanchez-Domínguez R, et al. Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia. J Clin Invest 2022; 132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagby GC. Multifunctional Fanconi proteins, inflammation and the Fanconi phenotype. EBioMedicine 2016; 8:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risitano AM, Marotta S, Calzone R, et al. Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned. Haematologica 2016; 101:319.
          </a>
         </li>
         <li class="breakAll">
          Alter BP. Inherited Bone Marrow Failure Syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan DG, Orkin SH, Ginsburg D, Look AT (Eds), W.B. Saunders, Philadelphia 2003. p.280.
         </li>
         <li class="breakAll">
          Young NS, Alter BP. Aplastic Anemia: Acquired and Inherited, WB Saunders, Philadelphia 1994. p.13.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tipping AJ, Pearson T, Morgan NV, et al. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc Natl Acad Sci U S A 2001; 98:5734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callén E, Casado JA, Tischkowitz MD, et al. A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood 2005; 105:1946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amouri A, Talmoudi F, Messaoud O, et al. High frequency of exon 15 deletion in the FANCA gene in Tunisian patients affected with Fanconi anemia disease: implication for diagnosis. Mol Genet Genomic Med 2014; 2:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamary H, Bar-Yam R, Shalmon L, et al. Fanconi anaemia group A (FANCA) mutations in Israeli non-Ashkenazi Jewish patients. Br J Haematol 2000; 111:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutler DI, Auerbach AD. Fanconi anemia in Ashkenazi Jews. Fam Cancer 2004; 3:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg PS, Tamary H, Alter BP. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. Am J Med Genet A 2011; 155A:1877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strom CM, Crossley B, Redman JB, et al. Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory. Genet Med 2004; 6:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magdalena N, Pilonetto DV, Bitencourt MA, et al. Frequency of Fanconi anemia in Brazil and efficacy of screening for the FANCA 3788-3790del mutation. Braz J Med Biol Res 2005; 38:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010; 24:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giampietro PF, Verlander PC, Davis JG, Auerbach AD. Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study. Am J Med Genet 1997; 68:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stivaros SM, Alston R, Wright NB, et al. Central nervous system abnormalities in Fanconi anaemia: patterns and frequency on magnetic resonance imaging. Br J Radiol 2015; 88:20150088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Törnquist AL, Martin L, Winiarski J, Fahnehjelm KT. Ocular manifestations and visual functions in patients with Fanconi anaemia. Acta Ophthalmol 2014; 92:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsilou ET, Giri N, Weinstein S, et al. Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia and dyskeratosis congenita. Ophthalmology 2010; 117:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vale MJ, Dinis MJ, Bini-Antunes M, et al. Audiologic abnormalities of Fanconi anaemia. Acta Otolaryngol 2008; 128:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tekcicek M, Tavil B, Cakar A, et al. Oral and dental findings in children with Fanconi anemia. Pediatr Dent 2007; 29:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Açikgöz A, Ozden FO, Fisgin T, et al. Oral and dental findings in Fanconi's anemia. Pediatr Hematol Oncol 2005; 22:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson-Tesch BA, Gawande RS, Zhang L, et al. Fanconi anemia: correlating central nervous system malformations and genetic complementation groups. Pediatr Radiol 2017; 47:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giampietro PF, Adler-Brecher B, Verlander PC, et al. The need for more accurate and timely diagnosis in Fanconi anemia: a report from the International Fanconi Anemia Registry. Pediatrics 1993; 91:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alter BP, Giri N. Thinking of VACTERL-H? Rule out Fanconi Anemia according to PHENOS. Am J Med Genet A 2016; 170:1520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vetro A, Iascone M, Limongelli I, et al. Loss-of-Function FANCL Mutations Associate with Severe Fanconi Anemia Overlapping the VACTERL Association. Hum Mutat 2015; 36:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikat B, Roll C, Schindler D, et al. X-linked recessive VACTERL-H due to a mutation in FANCB in a preterm boy. Clin Dysmorphol 2016; 25:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross M, Hanenberg H, Lobitz S, et al. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res 2002; 98:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo Ten Foe JR, Kwee ML, Rooimans MA, et al. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet 1997; 5:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregory JJ Jr, Wagner JE, Verlander PC, et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci U S A 2001; 98:2532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waisfisz Q, Morgan NV, Savino M, et al. Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat Genet 1999; 22:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leguit RJ, van den Tweel JG. The pathology of bone marrow failure. Histopathology 2010; 57:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol 2014; 27:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica 2018; 103:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rochowski A, Olson SB, Alonzo TA, et al. Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML. Pediatr Blood Cancer 2012; 59:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tönnies H, Huber S, Kuhl JS, et al. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 2003; 101:3872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood 2003; 101:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alter BP. Fanconi's anemia and malignancies. Am J Hematol 1996; 53:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer 2003; 97:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg PS, Socié G, Alter BP, Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood 2005; 105:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guardiola P, Socié G, Li X, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood 2004; 103:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malric A, Defachelles AS, Leblanc T, et al. Fanconi anemia and solid malignancies in childhood: a national retrospective study. Pediatr Blood Cancer 2015; 62:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutler DI, Wreesmann VB, Goberdhan A, et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003; 95:1718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alter BP, Giri N, Savage SA, et al. Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus. Int J Cancer 2013; 133:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Zeeburg HJ, Snijders PJ, Wu T, et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2008; 100:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petryk A, Kanakatti Shankar R, Giri N, et al. Endocrine disorders in Fanconi anemia: recommendations for screening and treatment. J Clin Endocrinol Metab 2015; 100:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose SR, Myers KC, Rutter MM, et al. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer 2012; 59:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elder DA, D'Alessio DA, Eyal O, et al. Abnormalities in glucose tolerance are common in children with fanconi anemia and associated with impaired insulin secretion. Pediatr Blood Cancer 2008; 51:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giri N, Batista DL, Alter BP, Stratakis CA. Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab 2007; 92:2624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantor SB, Guillemette S. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future Oncol 2011; 7:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramus SJ, Song H, Dicks E, et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst 2015; 107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 2010; 70:7353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinella JF, Healy J, Saillour V, et al. Whole-exome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals putative predisposing mutations in Fanconi anemia genes. BMC Cancer 2015; 15:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berwick M, Satagopan JM, Ben-Porat L, et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 2007; 67:9591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trujillo JP, Surralles J. Savior siblings and Fanconi anemia: analysis of success rates from the family's perspective. Genet Med 2015; 17:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rochowski A, Rosenberg PS, Alonzo TA, et al. Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy. Leuk Res 2012; 36:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auerbach AD. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol 1993; 21:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oostra AB, Nieuwint AW, Joenje H, de Winter JP. Diagnosis of fanconi anemia: chromosomal breakage analysis. Anemia 2012; 2012:238731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Lelij P, Oostra AB, Rooimans MA, et al. Diagnostic Overlap between Fanconi Anemia and the Cohesinopathies: Roberts Syndrome and Warsaw Breakage Syndrome. Anemia 2010; 2010:565268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartung HD, Olson TS, Bessler M. Acquired aplastic anemia in children. Pediatr Clin North Am 2013; 60:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah YB, Priore SF, Li Y, et al. The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis. Blood Adv 2021; 5:3216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 109795 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11110674" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12509764" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The Fanconi anaemia/BRCA pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16153896" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17200671" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24584348" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Molecular analysis of Fanconi anemia: the experience of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Onco-Hematology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26046368" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26596371" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Update of the human and mouse Fanconi anemia genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26119737" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Deficiency of UBE2T, the E2 Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T Subtype of Fanconi Anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26085575" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25472942" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26253028" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26681308" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27208205" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28691929" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11093276" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23613520" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393516" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A 20-year perspective on the International Fanconi Anemia Registry (IFAR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393516" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A 20-year perspective on the International Fanconi Anemia Registry (IFAR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27020090" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : How I treat MDS and AML in Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22160080" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8896564" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Positional cloning of the Fanconi anaemia group A gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8896563" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21273304" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7492758" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Carrier frequency of the IVS4 + 4 A--&gt;T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9207444" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15657175" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A common Fanconi anemia mutation in black populations of sub-Saharan Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12673805" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Two common founder mutations of the fanconi anemia group G gene FANCG/XRCC9 in the Japanese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25703136" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Founder haplotype analysis of Fanconi anemia in the Korean population finds common ancestral haplotypes for a FANCG variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16825431" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17148764" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : BRCA mutation frequency and penetrance: new data, old debate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15070707" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21548014" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26512453" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : What is the DNA repair defect underlying Fanconi anemia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29399332" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Recent advances in understanding hematopoiesis in Fanconi Anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34405046" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : An update on Fanconi anemia: Clinical, cytogenetic and molecular approaches (Review).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20713514" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Expanded roles of the Fanconi anemia pathway in preserving genomic stability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12893780" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The Fanconi road to cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25307146" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Fanconi anaemia: genetics, molecular biology, and cancer–implications for clinical management in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17768402" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16493006" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Molecular pathogenesis of Fanconi anemia: recent progress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16132046" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Unraveling the Fanconi anemia-DNA repair connection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16896009" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17431503" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25237197" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Stress and DNA repair biology of the Fanconi anemia pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27223997" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Fanconi Anemia: A DNA repair disorder characterized by accelerated decline of the hematopoietic stem cell compartment and other features of aging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24200684" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Why does the bone marrow fail in Fanconi anemia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15769896" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hypoxia-reoxygenation induces premature senescence in FA bone marrow hematopoietic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14764578" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Oxidant hypersensitivity of Fanconi anemia type C-deficient cells is dependent on a redox-regulated apoptotic pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18056434" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cells deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of formaldehyde.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24037726" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18477050" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Oxidative stress causes telomere damage in Fanconi anaemia cells - a possible predisposition for malignant transformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18055871" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Aberrant activation of stress-response pathways leads to TNF-alpha oversecretion in Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35671096" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27428405" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Multifunctional Fanconi proteins, inflammation and the Fanconi phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26635036" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26635036" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26635036" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11344308" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15522956" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24689079" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : High frequency of exon 15 deletion in the FANCA gene in Tunisian patients affected with Fanconi anemia disease: implication for diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11091222" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Fanconi anaemia group A (FANCA) mutations in Israeli non-Ashkenazi Jewish patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15516848" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Fanconi anemia in Ashkenazi Jews.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21739583" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15354333" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15917947" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Frequency of Fanconi anemia in Brazil and efficacy of screening for the FANCA 3788-3790del mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20417588" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pathophysiology and management of inherited bone marrow failure syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8986277" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26369989" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Central nervous system abnormalities in Fanconi anaemia: patterns and frequency on magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23648176" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Ocular manifestations and visual functions in patients with Fanconi anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20022637" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia and dyskeratosis congenita.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19086307" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Audiologic abnormalities of Fanconi anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17688024" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Oral and dental findings in children with Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16169820" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Oral and dental findings in Fanconi's anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28283722" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Fanconi anemia: correlating central nervous system malformations and genetic complementation groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8502512" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The need for more accurate and timely diagnosis in Fanconi anemia: a report from the International Fanconi Anemia Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27028275" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Thinking of VACTERL-H? Rule out Fanconi Anemia according to PHENOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25754594" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Loss-of-Function FANCL Mutations Associate with Severe Fanconi Anemia Overlapping the VACTERL Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26683739" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : X-linked recessive VACTERL-H due to a mutation in FANCB in a preterm boy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12697994" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9272737" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11226273" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10431244" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20727024" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The pathology of bone marrow failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25455269" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Fanconi anemia and the development of leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29051281" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22517793" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12511406" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393424" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cancer incidence in persons with Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8892734" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Fanconi's anemia and malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12518367" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Cancer in Fanconi anemia, 1927-2001.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15331448" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12946993" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25381700" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Fanconi anemia and solid malignancies in childhood: a national retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14625263" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23558727" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001603" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25575015" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Endocrine disorders in Fanconi anemia: recommendations for screening and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22294495" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Endocrine phenotype of children and adults with Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18454466" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Abnormalities in glucose tolerance are common in children with fanconi anemia and associated with impaired insulin secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17426088" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Endocrine abnormalities in patients with Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21345144" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26315354" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20858716" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : PALB2/FANCN: recombining cancer and Fanconi anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26201965" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Whole-exome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals putative predisposing mutations in Fanconi anemia genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17909071" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25674777" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Savior siblings and Fanconi anemia: analysis of success rates from the family's perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21974856" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8500573" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Fanconi anemia diagnosis and the diepoxybutane (DEB) test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22693659" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Diagnosis of fanconi anemia: chromosomal breakage analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21490908" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Diagnostic Overlap between Fanconi Anemia and the Cohesinopathies: Roberts Syndrome and Warsaw Breakage Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24237973" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Acquired aplastic anemia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34427585" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
